Systematic review of the clinical and genetic aspects of Prader-Willi syndrome.
- Author:
Dong Kyu JIN
1
Author Information
- Publication Type:Review
- Keywords: Prader-Willi syndrome; Genetics; Clinical manifestations; Growth hormone treatment
- MeSH: Body Composition; DNA Methylation; Early Diagnosis; Genomic Imprinting; Growth Hormone; Humans; Hyperphagia; Hypogonadism; Infant; Learning Disorders; Life Expectancy; Muscle Hypotonia; Obesity, Morbid; Phenotype; Prader-Willi Syndrome; Quality of Life; Uniparental Disomy
- From:Korean Journal of Pediatrics 2011;54(2):55-63
- CountryRepublic of Korea
- Language:English
- Abstract: Prader-Willi syndrome (PWS) is a complex multisystem genetic disorder that is caused by the lack of expression of paternally inherited imprinted genes on chromosome 15q11-q13. This syndrome has a characteristic phenotype including severe neonatal hypotonia, early-onset hyperphagia, development of morbid obesity, short stature, hypogonadism, learning disabilities, behavioral problems, and psychiatric problems. PWS is an example of a genetic condition caused by genomic imprinting. It can occur via 3 main mechanisms that lead to the absence of expression of paternally inherited genes in the 15q11.2-q13 region: paternal microdeletion, maternal uniparental disomy, and an imprinting defect. Over 99% of PWS cases can be diagnosed using DNA methylation analysis. Early diagnosis of PWS is important for effective long-term management. Growth hormone (GH) treatment improves the growth, physical phenotype, and body composition of patients with PWS. In recent years, GH treatment in infants has been shown to have beneficial effects on the growth and neurological development of patients diagnosed during infancy. There is a clear need for an integrated multidisciplinary approach to facilitate early diagnosis and optimize management to improve quality of life, prevent complications, and prolong life expectancy in patients with PWS.
